PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

ReBEC support is provided exclusively by official online channels.

Service channels:
* IA ReBEC@ (virtual assistant): automated service 24 hours a day, 7 days a week
* Humanized chat: from Monday to Friday, from 8 a.m. to 12 p.m. (Brasília time)
* Institutional WhatsApp / Dedicated line: +55 21 97203-4750
Service from Monday to Friday, from 9 a.m. to 4 p.m. (Brasília time)

Priority and/or urgent administrative demands outside the file schedule may be submitted to: plantao.rebec@gmail.com

We recommend that all requests be accompanied by a login, linked email or study registration number. (RBR-xxxxxxx), when applicable, for agility in attention.

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

07/10/2026  |   Andrea Lobo   |  Parkinson's News Today

https://parkinsonsnewstoday.com/news/trial-fast-tracked-new-parkinsons-cell-therapy-hits-critical-step/ 

2 groups get commercial 'thaw-and-inject' formulation of sasineprocel

Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial.

This brings the total number of adults with Parkinson’s who received sasineprocel in the ASPIRO trial (NCT06344026) to 15. The Phase 1/2a study, conducted at nine sites across the country, is testing the safety and tolerability of the autologous cell therapy — one that uses a patient’s own cells — for up to five years.

The treatment’s commercial formulation uses what its developer calls cryopreserved “thaw-and-inject” cells that can be administered upon arrival at the clinical site. It was developed to facilitate therapy production and clinical delivery.

“We are proud to reach this important milestone, which reflects meaningful progress in the sasineprocel program and underscores the growing clinical experience with our personalized, autologous approach,” Damien McDevitt, PhD, Aspen’s president and CEO, said in a company press release. “Importantly, the use of our commercial formulation in these [patient groups] represents a critical step toward scalable manufacturing and commercial readiness as we prepare for Phase 3 initiation.”

Sasineprocel is an autologous cell therapy, meaning an individual’s own cells are the basis for the treatment, that aims to replace dopaminergic neurons, the nerve cells lost in Parkinson’s…

07/09/2026  |  Estado de Minas

https://www.em.com.br/bem-viver/2026/07/amp/7458042-estudo-com-23-mil-pacientes-traz-evidencias-sobre-o-controle-do-diabetes.html 

Published in an international journal, Hapvida’s study evaluates the results of the Viver Bem program and highlights improvements in clinical and laboratory indicators

A study published in the international scientific journal BMC Endocrine Disorders on May 27 reveals that patients with type 2 diabetes (T2D) enrolled in the Viver Bem program—a structured diabetes care initiative adopted by Hapvida—showed significant improvements in clinical and laboratory indicators.

Factors such as glycated hemoglobin, blood pressure, weight, and lipid profile were monitored in 23,516 enrolled patients over approximately 20 months, between 2017 and 2023.

In addition to improvements in these indicators, lower operational costs related to emergency room visits, tests, and treatments were recorded compared to eligible patients who were not included in the program.
The study, conducted by the Hapvida Clinical Research Center in partnership with the Federal University of São Paulo and Nove de Julho University, is one of the largest real-world studies on diabetes management ever conducted in Brazil within a supplemental health care system.

“Follow-up of patients included in the program shows that structured chronic care delivers real clinical benefits. Furthermore, a rational strategy for resource allocation can help make health plans more sustainable and accessible. Programs like this demonstrate that providing good care costs less,” says Rodrigo Sardenberg, director of clinical research at Hapvida.

Continuous Monitoring

The Viver Bem Program…

07/10/2026  |  Paloma Oliveto  |  Correio Brasiliense

https://www.correiobraziliense.com.br/ciencia-e-saude/2026/07/7458373-estudo-testa-transplante-de-celulas-como-tratamento-para-parkinson.html 

In a preliminary study involving eight patients, scientists demonstrated the safety of the procedure, which uses embryonic tissue reprogrammed to become neurons. There is still a long way to go before clinical application, but the authors are optimistic

For decades, the treatment of Parkinson’s disease has focused on alleviating the symptoms caused by the progressive loss of neurons that produce dopamine, which is currently achieved through the use of medications. Now, a human study points to a new therapeutic approach: replacing destroyed brain cells with new structures of embryonic origin, genetically programmed to naturally produce the neurotransmitter.

In Parkinson’s disease, the brain loses nerve cells that produce dopamine, leading to symptoms such as slowness of movement, rigidity, gait disturbances, and tremors. Although the most modern medications have revolutionized the treatment of the disease, improving patients’ quality of life, over time these substances often become less effective and can cause neurological, gastrointestinal, and psychiatric side effects, among others.

To address these limitations, researchers from England, Sweden, and the United States tested the safety of transplanting dopamine-producing neurons derived from embryonic stem cells into the brain. As this is still a preliminary study, the research—published in the journal *Nature Medicine* and presented yesterday at the annual meeting of the International Society for Stem Cell Research in Montreal, Canada—was conducted with only eight…

07/09/2026  |  Júlia Moreira/Tribuna do Paraná  |  Gazeta do Povo

https://www.gazetadopovo.com.br/parana/parana-lidera-aplicacoes-de-polilaminina/ 

Paraná ranks first in Brazil in the number of polylaminine treatments. As of the end of June, the state had performed 19 procedures using the experimental drug for the treatment of spinal cord injuries, according to data from Laboratório Cristália. This total surpasses the figures for Rio de Janeiro, with 11 applications, and Espírito Santo, with nine. In all, 19 states have already performed at least one application of the substance.

The treatment, which has shown promising results in the recovery of patients with spinal cord injuries, was administered for the first time in Paraná on January 8 of this year at Santa Casa de Maringá. In Curitiba, the first administration took place on March 3, 2026, at Hospital do Trabalhador.

Still in the experimental phase, the drug is used in ongoing clinical trials and also for compassionate use. The Brazilian Health Regulatory Agency (Anvisa) grants authorization for this type of use through an administrative process, but the decision to donate the drug rests with the pharmaceutical company.

Polylaminin administration requires precision in the lesion area
The procedure involves a puncture directly into the affected area. “In layman’s terms, it’s an injection, but technically speaking, it’s a spinal puncture. We go to the patient, study the location of the injury beforehand, and need to be literally surgical. It’s an area of approximately one square centimeter,” explained neurosurgeon João Elias Ferreira El Sarraf, who lives in Paraná and is one of four doctors responsible for administering polylaminin…

07/09/2026  |  Ahmed Obeidat/Isabella Ciccone  |  Neurology Live

https://www.neurologylive.com/view/rethinking-clinical-trial-design-immune-system-ms-ahmed-obeidat 

At CMSC 2026, the associate professor of neurology at the Medical College of Wisconsin discussed the need to reconsider clinical trial paradigms by recognizing the role of immune cells 

"I want to challenge the concept that the immune system is our enemy in this disease. I want to think of it as maybe as our friend who's just a little bit misbehaving, and we need to put it back in check. We want to redirect the immune system."
Reimagining clinical trial design in multiple sclerosis (MS) has become increasingly important as limitations of traditional efficacy measures, such as relapse rates and MRI lesion activity, have come into sharper focus. Emerging evidence suggests that neurodegeneration and disease progression may continue despite apparent control of inflammatory activity, underscoring the need for end points and therapeutic strategies that prioritize preservation of brain tissue and long-term neurologic function. As understanding of the immunopathology of MS evolves, researchers are reconsidering the role of immune cells not only as drivers of injury, but also as potential mediators of repair and neuroprotection.

At the recently concluded 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 27-29, Charlotte, North Carolina, MS specialist Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, presented a session titled “Changing the Rules: Reimagining Clinical Trials in Multiple Sclerosis.” In this talk, he explored how conventional paradigms that focus predominantly on immune suppression and inflammatory activity may…